These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3156964)

  • 21. Treatment of Huntington's chorea with bromocriptine.
    Frattola L; Albiazzati MG; Spano PF; Trabucchi M
    Acta Neurol Scand; 1977 Jul; 56(1):37-45. PubMed ID: 141860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bromocriptine in Huntington chorea.
    Kartzinel R; Hunt RD; Calne DB
    Arch Neurol; 1976 Jul; 33(7):517-8. PubMed ID: 132915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy.
    Meltzer HY; Kolakowska T; Robertson A; Tricou BJ
    Psychopharmacology (Berl); 1983; 81(1):37-41. PubMed ID: 6415730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of choreic movements with perphenazine.
    Fahn S
    Dis Nerv Syst; 1972 Oct; 33(10):653-8. PubMed ID: 4265163
    [No Abstract]   [Full Text] [Related]  

  • 25. Pergolide, a potent long-acting dopamine-receptor agonist.
    Lemberger L; Crabtree R; Callaghan JT
    Clin Pharmacol Ther; 1980 May; 27(5):642-51. PubMed ID: 7189453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apomorphine: chemistry, pharmacology, biochemistry.
    Colpaert FC; Van Bever WF; Leysen JE
    Int Rev Neurobiol; 1976; 19():225-68. PubMed ID: 13044
    [No Abstract]   [Full Text] [Related]  

  • 27. Dopamine receptor sensitivity in the hypothalamus of chronic schizophrenics after haloperidol therapy: growth hormone and prolactin response to stimuli.
    Brambilla F; Bellodi L; Negri F; Smeraldi E; Malagoli G
    Psychoneuroendocrinology; 1979 Oct; 4(4):329-39. PubMed ID: 523590
    [No Abstract]   [Full Text] [Related]  

  • 28. Bromocriptine and dopaminergic function in Huntington disease.
    Loeb C; Roccatagliata G; Albano C; Besio G
    Neurology; 1979 May; 29(5):730-4. PubMed ID: 155784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 3-PPP, a putative dopamine autoreceptor agonist, on rat serum prolactin levels.
    Meltzer HY; Simonovic M
    Life Sci; 1981 Jul; 29(1):99-105. PubMed ID: 7196483
    [No Abstract]   [Full Text] [Related]  

  • 30. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of dopamine in the inhibitory control of growth hormone and prolactin release by gastrin-releasing peptide.
    Kentroti S; McCann SM
    Brain Res Bull; 1996; 39(4):201-4. PubMed ID: 8963684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sleep deprivation on dopamine receptor function in normal subjects.
    Lal S; Thavundayil J; Nair NP; Etienne P; Rastogi R; Schwartz G; Pulman J; Guyda H
    J Neural Transm; 1981; 50(1):39-45. PubMed ID: 7205248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The putatively selective dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 stimulate prolactin release in rats.
    Svensson K; Carlsson M; Carlsson A; Hjorth S; Johansson AM; Eriksson E
    Eur J Pharmacol; 1986 Nov; 130(3):237-42. PubMed ID: 3792447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma growth hormone concentrations in Huntington's chorea.
    Phillipson OT; Bird ED
    Clin Sci Mol Med; 1976 Jun; 50(6):551-4. PubMed ID: 132332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea.
    Kartzinel R; Perlow MD; Carter AC; Chase TN; Calne DB; Shoulson I
    Trans Am Neurol Assoc; 1976; 101():53-6. PubMed ID: 141763
    [No Abstract]   [Full Text] [Related]  

  • 36. Impaired prolactin release in Huntington's chorea. Evidence for dopaminergic excess.
    Hayden MR; Vinik AI; Paul M; Beighton P
    Lancet; 1977 Aug; 2(8035):423-6. PubMed ID: 70642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homovanilic acid in Huntington's disease and Sydenham's chorea.
    Cunha L; Oliveira CR; Diniz M; Amaral R; Conçalves AF; Pio-Abreu J
    J Neurol Neurosurg Psychiatry; 1981 Mar; 44(3):258-61. PubMed ID: 6453208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect on plasma prolactin, growth hormone and luteinising hormone concentrations of single oral doses or propranolol and tolamolol in normal man.
    Saxton CA; Faulkner JK; Groom GV
    Eur J Clin Pharmacol; 1981; 21(2):103-8. PubMed ID: 6896183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for a dopaminergic activity of methysergide in humans.
    Oppizzi G; Verde G; De Stefano L; Cozzi R; Botalla L; Liuzzi A; Chiodini PG
    Clin Endocrinol (Oxf); 1977 Oct; 7(4):267-72. PubMed ID: 923106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.